Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Precipio, Inc.PRPO · Entity 7207 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Precipio, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectWythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | 3,000 |
Reported balance
After 2026-05-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-21 · Sale · Disposed 900 · Balance 3,000 F1: Shares disposed in open market transactions by Wythburn Associates, Ltd, which is 94% owned jointly by the reporting person and their spouse. The reporting person disclaims beneficial ownership of the securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 8,142 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,142 |
| Common StockSEC Table I · non-derivative | IndirectRoth IRA for the benefit of Richard A Sandberg | 25,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares disposed in open market transactions by Wythburn Associates, Ltd, which is 94% owned jointly by the reporting person and their spouse. The reporting person disclaims beneficial ownership of the securities except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.86 · Expires 2024-06-12 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 6,107 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2016 Filed Nov 9, 2016 21:41 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleORDINARY SHARES | 200 | $14.15 | $2,830.00 |
DisclosureSEC source: 0001437749-16-041579 · rdgdoc.xml · nonDerivative · entry 4 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,674 Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:41 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleORDINARY SHARES | 400 | $14.20 | $5,680.00 |
DisclosureSEC source: 0001437749-16-041579 · rdgdoc.xml · nonDerivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,874 Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:41 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleORDINARY SHARES | 1,500 | $14.17 | $21,255.00 |
DisclosureSEC source: 0001437749-16-041579 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,274 Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:41 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleORDINARY SHARES | 400 | $14.19 | $5,674.00 |
DisclosureSEC source: 0001437749-16-041579 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,774 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.